Avastin-Tarceva combo fails in lung cancer trial
Genentech Inc. and OSI Pharmaceuticals Inc. said Monday a combination of two cancer drugs missed its primary goal in a clinical trial, failing to improve survival for patients with lung cancer.
This entry was posted on Monday, October 6th, 2008 at 1:25 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.